The platform technology can be adapted to assess a vast array of biomarkers present in the eye.
Zilia, a medical technology company specializing in the non-invasive assessment of ocular biomarkers, this week announced it has received FDA clearance for its Zilia Ocular FC retinal camera.
Based in Quebec City, Canada, Zilia’s Ocular FC system is designed for assessing ocular biomarkers.1 The company noted in a previous news release its technology aims to allow for the early diagnosis and management of a range of ocular diseases.2
The platform technology can be adapted to assess a vast array of biomarkers present in the eye, paving the way for other applications in neurology, cardiology, oncology, and more.
Patrick Sauvageau, OD, MSc, CEO, and co-founder of Zilia, said the approval marked a milestone in the company’s history.
"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," Sauvageau said in the company’s news release. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."